GPX4-IN-6 manufacturers
- GPX4-IN-6
-
-
2026-08-16
- CAS:2922824-07-3
- Purity: 99.57%
- Supply Ability: 10g
|
| | GPX4-IN-6 Basic information |
| Product Name: | GPX4-IN-6 | | Synonyms: | GPX4-IN-6;2-Bromo-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-N-(4-fluoro-3,5-dimethoxyphenyl)acetamide;Acetamide, 2-bromo-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(4-fluoro-3,5-dimethoxyphenyl)-;GPX4-IN-6, 10 mM in DMSO | | CAS: | 2922824-07-3 | | MF: | C18H17BrFNO5 | | MW: | 426.23 | | EINECS: | | | Product Categories: | | | Mol File: | 2922824-07-3.mol |  |
| | GPX4-IN-6 Chemical Properties |
| Boiling point | 644.7±55.0 °C(predicted) | | density | 1.511±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | -4.51±0.20(predicted) | | form | Solid | | color | White to off-white |
| | GPX4-IN-6 Usage And Synthesis |
| Uses | GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) [1]. | | References | [1] Chen T, et al. Discovery of Novel Potent Covalent Glutathione Peroxidase 4 Inhibitors as Highly Selective Ferroptosis Inducers for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2023 Jul 27;66(14):10036-10059. DOI:10.1021/acs.jmedchem.3c00967 |
| | GPX4-IN-6 Preparation Products And Raw materials |
|